CCN5 and breast cancer: Treatment with estradiol activates synthetically produced CCN5 (hrCCN5), possibly through autocrine-paracrine feedback signalling loop involving CCN5 and ER-α that regulates these molecules, and activates CCN5 transcription in triple-negative BC [40].